Enzyme-replacement therapy for Anderson-Fabry disease
- 1 August 2001
- journal article
- Published by Elsevier in The Lancet
- Vol. 358 (9282) , 601-603
- https://doi.org/10.1016/s0140-6736(01)05816-0
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier femalesJournal of Medical Genetics, 2001
- Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous malesJournal of Medical Genetics, 2001
- Improvement in Cardiac Function in the Cardiac Variant of Fabry's Disease with Galactose-Infusion TherapyNew England Journal of Medicine, 2001
- Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's DiseaseNew England Journal of Medicine, 2001
- Enzyme Replacement Therapy in Fabry DiseaseJAMA, 2001
- A Phase 1/2 Clinical Trial of Enzyme Replacement in Fabry Disease: Pharmacokinetic, Substrate Clearance, and Safety StudiesAmerican Journal of Human Genetics, 2001
- Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry miceProceedings of the National Academy of Sciences, 2001
- Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivationJournal of Clinical Investigation, 2000
- Prevalence of Lysosomal Storage DisordersJAMA, 1999
- An Atypical Variant of Fabry's Disease in Men with Left Ventricular HypertrophyNew England Journal of Medicine, 1995